arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

AbCellera Biologics Inc.

ABCL Health Care Biotechnology: Pharmaceutical Preparations
$11.82
▼ -3.4% Today
as of Oct 23, 16:45 ET
Last 30 days +5.82% Sep 14 → Oct 23
$10.88 $11.94 $12.99 $14.05 $15.11 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$11.45
High
$11.89
Low
$11.08
Volume
$3M
Avg Vol
$6M
Mkt Cap
$4.5B
P/E (TTM)
—
Beta
—
52w High
$15.02
52w Low
$2.75
Div Yield
—
Shares Out
$306M

Recent Press Releases & News last 60 days · 12 items

Oct 22 · 20:05 PR Business Wire
AbCellera to Present at Upcoming Investor Conferences in November 2026
Oct 12 · 16:55 MT Newswires
AbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS Says
Oct 12 · 11:35 MT Newswires
UBS Initiates AbCellera Biologics at Buy With $18 Price Target
▸ Show all 12 press releases & news Free account →

ABCL earnings at a glance

The options market is pricing a move of about ±9.7% after the report, a range of roughly $10.67 to $12.97 from today's $11.82. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±0.1% on average; after the most recent report on May 11, 2026 it moved +0.2%. That means options currently expect more movement than ABCL has typically delivered. ABCL beat the consensus EPS estimate in 3 of its last 4 reported quarters. Implied volatility is currently 82%. The share price of $11.82 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$2.75
$15
74% of range
Avg surprise (last 4)
+16.4%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
82%
EM ±9.7% · $12 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.22$-0.19$-0.16$-0.13$-0.10 Actual $-0.14Actual $-0.11Actual $-0.10Actual $-0.14Actual $-0.13Actual $-0.17Actual $-0.15Est $-0.17Actual $-0.12Est $-0.17Actual $-0.19Est $-0.17Actual $-0.14Est $-0.22Actual $-0.18 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-57M$-38M$-20M$-826,100$18M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.18 — — — — financials
Mon May 11, 2026Mar/2026 $-0.14 $-0.22 +36.4% +6.7% +0.2% earnings
Thu Nov 6, 2025Sep/2025 $-0.19 $-0.17 -11.8% — — earnings
Thu Aug 7, 2025Jun/2025 $-0.12 $-0.17 +29.4% — — earnings
Thu May 8, 2025Mar/2025 $-0.15 $-0.17 +11.8% — 0.0% earnings
Mon Sep 30, 2024Sep 2024 $-0.17 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.13 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.14 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.10 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.11 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.14 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$4M$8M—$9M$17M$4M—$7M
Cost of revenue————————
Gross profit————————
Operating income$-63M$-58M—$-76M$-50M$-63M—$-94M
Net income$-55M$-43M—$-57M$-35M$-46M—$-51M
EPS (diluted)$-0.18$-0.14—$-0.19$-0.12$-0.15—$-0.17

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$120M$77M$129M$83M$92M$159M$156M$127M
Inventory$8M$8M$6M—————
Total current assets$679M$665M$728M$695M$742M$765M$751M$743M
Total assets$1.31B$1.31B$1.36B$1.36B$1.40B$1.34B$1.36B$1.39B
Long-term debt————————
Total liabilities$412M$369M$390M$392M$395M$321M$304M$315M
Total equity$896M$938M$967M$964M$1.01B$1.02B$1.06B$1.08B

Implied volatility — last 90 days

36%150%264%378%492% Jun 07 — IV 132% · EM ±18.2%Jun 08 — IV 146% · EM ±19.3%Jun 09 — IV 142% · EM ±17.8%Jun 10 — IV 122% · EM ±14.5%Jun 11 — IV 119% · EM ±13.2%Jun 12 — IV 121% · EM ±12.4%Jun 15 — IV 120% · EM ±8.7%Jun 16 — IV 133% · EM ±7.9%Jun 17 — IV 493% · EM ±20.6%Jun 19 — IV 113% · EM ±24.9%Jun 22 — IV 94% · EM ±19.6%Jun 23 — IV 104% · EM ±21.2%Jun 24 — IV 106% · EM ±21.2%Jun 25 — IV 110% · EM ±21.6%Jun 26 — IV 106% · EM ±20.2%Jun 29 — IV 111% · EM ±19.7%Jun 30 — IV 122% · EM ±21.0%Jul 01 — IV 122% · EM ±20.4%Jul 02 — IV 114% · EM ±18.5%Jul 03 — IV 118% · EM ±18.5%Jul 06 — IV 121% · EM ±16.7%Jul 07 — IV 123% · EM ±16.3%Jul 08 — IV 128% · EM ±16.1%Jul 09 — IV 110% · EM ±13.0%Jul 10 — IV 111% · EM ±12.3%Jul 13 — IV 133% · EM ±11.1%Jul 14 — IV 148% · EM ±10.7%Jul 15 — IV 144% · EM ±8.5%Jul 16 — IV 175% · EM ±7.3%Jul 20 — IV 110% · EM ±26.1%Jul 21 — IV 110% · EM ±25.5%Jul 22 — IV 115% · EM ±26.3%Jul 23 — IV 106% · EM ±23.8%Jul 24 — IV 101% · EM ±22.3%Jul 27 — IV 75% · EM ±15.7%Jul 28 — IV 109% · EM ±22.2%Jul 29 — IV 102% · EM ±20.4%Jul 30 — IV 100% · EM ±19.6%Jul 31 — IV 98% · EM ±18.8%Aug 03 — IV 116% · EM ±20.6%Aug 04 — IV 102% · EM ±17.5%Aug 05 — IV 116% · EM ±19.3%Aug 06 — IV 99% · EM ±16.0%Aug 07 — IV 93% · EM ±14.5%Aug 10 — IV 88% · EM ±12.2%Aug 11 — IV 93% · EM ±12.3%Aug 12 — IV 81% · EM ±10.2%Aug 13 — IV 83% · EM ±9.8%Aug 14 — IV 84% · EM ±9.2%Aug 17 — IV 104% · EM ±8.7%Aug 18 — IV 109% · EM ±7.9%Aug 19 — IV 109% · EM ±6.4%Aug 20 — IV 202% · EM ±8.4%Aug 24 — IV 86% · EM ±17.9%Aug 25 — IV 88% · EM ±18.0%Aug 26 — IV 82% · EM ±16.4%Aug 27 — IV 83% · EM ±16.3%Aug 28 — IV 86% · EM ±16.5%Aug 31 — IV 76% · EM ±13.5%Sep 01 — IV 73% · EM ±12.5%Sep 02 — IV 80% · EM ±13.4%Sep 03 — IV 86% · EM ±13.8%Sep 04 — IV 84% · EM ±13.1%Sep 07 — IV 95% · EM ±13.1%Sep 08 — IV 80% · EM ±10.5%Sep 09 — IV 80% · EM ±10.0%Sep 10 — IV 68% · EM ±8.1%Sep 11 — IV 96% · EM ±10.6%Sep 14 — IV 94% · EM ±7.8%Sep 15 — IV 112% · EM ±8.1%Sep 16 — IV 36% · EM ±2.1%Sep 17 — IV 108% · EM ±4.5%Sep 21 — IV 91% · EM ±19.0%Sep 22 — IV 90% · EM ±18.4%Sep 23 — IV 77% · EM ±15.4%Sep 24 — IV 93% · EM ±18.2%Sep 25 — IV 81% · EM ±15.6%Sep 28 — IV 87% · EM ±15.4%Sep 29 — IV 104% · EM ±17.8%Sep 30 — IV 101% · EM ±16.8%Oct 01 — IV 82% · EM ±13.3%Oct 02 — IV 90% · EM ±14.0%Oct 05 — IV 102% · EM ±14.1%Oct 06 — IV 82% · EM ±10.8%Oct 07 — IV 75% · EM ±9.4%Oct 08 — IV 82% · EM ±9.7%

Sector peers

GMAB
Genmab A/S
$4.7B $43.79+10.7%
INDV
Indivior Pharmaceuticals, Inc.
$4.3B $34.47-0.9%
DNTH
Dianthus Therapeutics, Inc.
$4.7B $76.78-1.7%
ERAS
Erasca, Inc.
$5.1B $14.39-0.7%
TLX
Telix Pharmaceuticals Limited
$3.9B $9.15-8.8%
CPRX
Catalyst Pharmaceuticals, Inc.
$3.9B $31.49

ABCL earnings FAQ

What is ABCL's expected move for earnings?

Options currently price a move of about ±9.7%, or $1.15 per share either way from $11.82.

How does ABCL stock usually react to earnings?

Across the last 2 reports the average next-day move was ±0.1%, up 1 times and down 1 times.

What is ABCL's implied volatility?

ABCL's at-the-money implied volatility is about 82% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in